Search Results
Results found for "Gator Bio"
- Targeted Therapies to Reduce Side Effects in Modern Drug Development
Modern drug development approaches include a range of techniques leveraging structural biology, immunology
- Drug Discovery Picks Up the Pace, Stays on Target
technologies that stabilize G protein–coupled receptors (GPCRs) to enable the discovery of agonistic biologics
- Discovery On Target, October 17-20, 2022, Boston, USA
target validation strategies for the discovery and development of novel therapeutic agents ranging from biologics
- Pharmacophore-guided Virtual Screening to Identify New β 3 -adrenergic Receptor Agonists
Therefore, this study aimed to conduct prospective virtual screening and confirm the biological activity
- Trevena Reports Second Quarter 2022 Results and Provides Business Update
(Nasdaq:TRVN), a biopharmaceutical company focused on the development and commercialization of novel
- Discovery of 3(2-aminoethyl)-thiazolidine-2,4-diones as a novel chemotype of sigma-1 receptor ligand
It is classified into two types: Sigma-1 (S1R) and Sigma-2 (S2R) based on their biological functions.
- Actions of Parathyroid Hormone Ligand Analogues in Humanized PTH1R Knockin Mice
Expression is directed by the endogenous mouse promoter and hence occurs in all biologically relevant
- Therapeutic validation of an orphan G protein-coupled receptor: The case of GPR84
, recent developments and use of GPR84 pharmacological tool compounds to study its broader role and biology
- Amgen to Acquire Chemocentryx for $4 Billion in Cash
Calif., Aug. 4, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc., (NASDAQ: CCXI), a biopharmaceutical
- Anatomy of a partnership: Cancer Research UK teams up with Sosei Heptares
August 2022 "August 10, 2022 Cancer Research UK is working with global biopharma Sosei Heptares on a
- Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in...
(NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative
- X4 slashes pipeline, lays off staff just three weeks after netting a $55M PIPE
The Boston biotech revealed Wednesday afternoon that it would downsize its research to focus on its lead
- Tectonic Therapeutic Strengthens Leadership Team
July 19, 2022 07:00 AM Eastern Daylight Time BOSTON--Tectonic Therapeutic, Inc. a pre-clinical stage biotechnology Barry Rubenstein as Senior Vice President, People and Culture and Washington Alves as Vice President, Biologics
- Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate ...
Cambridge, UK, 22 July 2022 – Sosei Group Corporation (“the Company”; TSE: 4565), an international biopharmaceutical
- Third Rock pushes newest fund over $1B line as it marks 15 years in venture capital
That money has gone to some 60 biotechs, much of it as early funding."
- Michel Bouvier appointed Knight of the Ordre national du Québec
Principal Investigator of the Molecular Pharmacology Research Unit and Professor in the Department of Biochemistry
- Sosei Heptares and Kallyope Enter Collaboration to Identify and Validate Novel Gastrointestinal GPCR
will gain unique and valuable access to the Sosei Heptares compound library for its industry-leading biology Japan, Cambridge, UK and New York, USA – May 17, 2022 – Sosei Group Corporation, the international biopharmaceutical
- Inversago Pharma appoints Glenn S. Vraniak as Chief Financial Officer
(“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today Vraniak served as Chief Financial Officer of Evaxion Biotech A/S, an AI enabled immuno-oncology company
- GPCR Therapeutics Expands Scientific Advisory Board
South Korea, 28 April 2022 – GPCR therapeutics, Inc., a venture-backed clinical stage international biopharmaceutical
- Domain Therapeutics Raises $42m Series A Financing
best-in-class and first-in-class immuno-oncology programs STRASBOURG, France & MONTREAL- Domain Therapeutics, a biopharmaceutical round co-led by Panacea Venture, CTI Life Sciences and 3B Future Health Fund, and joined by adMare BioInnovations , Schroders Capital, Omnes, Turenne Capital, Theodorus, Viva BioInnovator and existing investor Seventure
- Design Pharmaceuticals Closes $5 Million Pre-series A Round to Accelerate Commercialization of ...
Design Pharmaceuticals’ platform is based on ultrahigh-throughput technologies that biomine drug-like
- Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare ...
(Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel
- Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ...
(Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel
- Sosei Heptares Confirms Senior Leadership Changes to Drive the Company Through the Next Stage ...
been approved at the Company’s 32nd Shareholders’ Meeting today and are effective immediately (see biographies
- Inversago Pharma Announces Dosing of First Participant with Metabolic Syndrome in Phase 1B ...
(“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announced
- Domain Therapeutics and Explicyte enter partnership agreement in immuno-oncology
Strasbourg and Bordeaux, France, March 10, 2022 – Domain Therapeutics, a biopharmaceutical company specializing The two companies will combine their expertise to identify GPCR targets and associated biomarkers to
- Crinetics Pharmaceuticals Expands Executive Team With Appointment Of James Hassard As Chief ...
than three decades of experience leading sales and marketing operations for both global and domestic biotechnology
- Trevena Announce Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu ...
commercialization milestones, as well as a 10% royalty on net sales in China CHESTERBROOK, Pa., Jan. 27, 2022 A biopharmaceutical
- Integration and Spatial Organization of Signaling by G Protein-Coupled Receptor Homo- and ...
Information exchange and interpretation is essential in biology and understanding how cells integrate information-coding molecules into complex orchestrated responses is a major challenge for modern cell biology new ideas about the physiological role played by receptor homo- and hetero-oligomerization in cell biology
- Phospholipid Scrambling by G Protein-Coupled Receptors
Rapid flip-flop of phospholipids across the two leaflets of biological membranes is crucial for many Expected final online publication date for the Annual Review of Biophysics, Volume 51 is May 2022.
